Sarama Resources (SRR:AU) has announced Q1 2025 Management’s Discussion and Analysis Download the PDF here. This post appeared first on investingnews.com
Category:
Investing
-
-
-
-
-
-
-
-
-
Investing
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
by adminDSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first…
-